

17th Oncology Update: Advances and Controversies
January 18-21, 2019

Friday, January 18, 2019

6:30am	Registration
6:50	Welcome Remarks Merrick I. Ross, MD
Session I	Prevention and Screening <i>Moderator: Merrick I. Ross, MD</i>
7:00-8:15am	Results of Lung Cancer Screening: Have Improved Outcomes Been Realized? Jeremy J. Erasmus, MBCh
	Melanoma Primary Prevention Initiatives: Education and Legislation* Jeffrey E. Gershenwald, MD
	HPV Vaccination: Penetration, Efficacy, and Expanding the Indications* Kathleen M. Schmeler, MD
	Anal Cancer: Etiology, Epidemiology, and Prevention Craig A. Messick, MD
Session II	Outcomes and Palliative Care <i>Moderator: Merrick I. Ross, MD</i>
8:15-9:10am	Patient Reported Outcomes: Does This Improve the Patient Care Experience?* Thomas A. Aloia, MD
	Integrating Cancer Care Quality Into National Public Reporting and Pay-for-Performance Programs* Karl Y. Bilimoria, MD
	Early Integration of the Palliative Care Team: Impact on Outcomes* Sririan Yennu, MD
Keynote Presentation	
9:10-9:30am	Anti-Cancer Living: Keys to Reduce Risk and Support Treatment* Lorenzo Cohen, PhD
10:00am-Noon	Meet the Professor
Session III	Plenary Session <i>Moderator: Merrick I. Ross, MD</i>
5:00-8:30pm	Immunotherapy Symposium
	PD-1 Resistance: Definitions, Frequency, and Biomarkers and Treatment Strategies Hussein A. Tawbi, MD
	Oncolytic (Intralesional) Immunotherapy: Can We Make a “Cold” Tumor “Hot”? Robert H. Andtbacka, MD
	Checkpoint Blockade and XRT: What is the Evidence for Synergism and an “Abscopal” Effect James W. Welsh, MD
	The Role of the Microbiome in the Response to Immunotherapy: The “Scoop is in the Poop” Jennifer Wargo, MD

Panel Q & A

Promising Actionable Biomarkers From Phase I Studies

Funda Meric-Bernstam, MD

Prospects for CAR-T and N-K Therapies in Solid Tumors

Stefan O. Ciurea, MD

Novel Nanoparticle Technology to Detect Micrometastatic Disease

Charles M. Balch, MD

Diagnosis and Management of Treatment-Related Toxicities

Cutaneous Toxicities of Targeted- and Immuno-Therapies

Joel Claveau, MD

Immune-Related Visceral Organ Toxicities

Isabella C. Glitza, MD, PhD

Lymphedema: Severity Assessment and Surgical Intervention

Edward I. Chang, MD

8:30-9:30pm

Welcome Reception

The lectures indicated with an * have been designated by The University of Texas MD Anderson Cancer Center for 1.75 *AMA PRA Category 1 Credits™* in medical ethics and/or professional responsibility.

Saturday, January 19, 2019

Session IV	Thoracic Oncology <i>Moderator:</i> Stephen G. Swisher, MD
7:30-9:30am	Evolving Front-Line Therapy for Stage 3 NSCLC: Results of the Pacific Trial James W. Welsh, MD Advances in the Treatment of Metastatic NSCLC John V. Heymach, MD, PhD Survival Outcomes for Local Therapy of Oligo-Metastatic NSCLC: Surgery or Radiation Therapy Stephen G. Swisher, MD New Paradigm in the Treatment of Small-Cell Lung Cancer Quynh-Nhu Nguyen, MD Chemo-Radiation for Advanced Esophageal Cancer: Front-Line Results and the Role if Any for Salvage Surgery Wayne L. Hofstetter MD Panel Q & A Case Presentations <i>Moderator:</i> Stephen G. Swisher, MD Panel: All Speakers
10:00am-Noon	Meet the Professor
Session V	Breast and Gynecological Cancer <i>Moderator:</i> Kelly K. Hunt, MD
4:30-7:30pm	Results from the Taylor Rx Trial: Impact on Clinical Practice Mariana Chavez-MacGregor, MD Novel Approaches to the Axilla in Node Positive Breast Cancer After Neo-Adjuvant Therapy Kelly K. Hunt, MD New Controversies in the Treatment of Breast Cancer Patients with Residual Disease After Neo-Adjuvant Therapy Mariana Chavez-MacGregor, MD Adjuvant Radiation Therapy for Breast Cancer: Current Controversies Thomas Buchholz, MD Immunotherapy for Breast Cancer: Is Progress Finally Being Made? Elizabeth A. Mittendorf, MD BRCA as a Biomarker for PARP Inhibition in Breast and Ovarian Cancer? Jennifer K. Litton, MD Value of Establishing a Tumor Registry for Rare Gynecological Malignancies Michael M. Frumovitz, MD Panel Q & A Case Presentations <i>Moderator:</i> Rosa F. Hwang, MD Panel: All Speakers; David M. Adelman, MD; Lavinia P. Middleton, MD; Aysegul A. Sahin, MD

Sunday, January 20, 2019

Session VI	Urology <i>Moderator:</i> Christopher G. Wood, MD
7:00-9:30am	Making the Case for Treating Primary Prostate Cancer Robotic Prostatectomy John W. Davis, MD External Beam Radiation Andrew K. Lee, MD, MPH MRI Guided Brachytherapy Steven J. Frank, MD Surveillance Neema Navai, MD Advances in Systemic Therapy for Aggressive Variant Prostate Cancer Ana Aparicio, MD Does Control of the Primary Tumor Improve Outcomes in Metastatic GU Cancers? Prostate Cancer Brian F. Chapin, MD Renal Cell Christopher G. Wood, MD Debate: cNO Metastatic Testicular Cancer After BEP Chemotherapy Bradley C. Leibovich, MD R. Houston Thompson, MD Panel Q & A Case Presentations <i>Moderator:</i> Christopher G. Wood, MD Panel: All Speakers
10:00am-Noon	Meet the Professor

Session VII**GI Oncology**

Moderator: Robert A. Wolff, MD

4:30-7:30pm

Novel Neo-Adjuvant Approaches for Resectable Pancreas Cancer

Jason B. Fleming, MD

Definitive Radiation Therapy for Hepatobiliary Cancer:**Can This Replace Surgical Resection?**

Christopher Crane, MD

Update on the Multi-Disciplinary Management of Midgut Carcinoid Tumors

Steven A. Curley, MD

Evolving Strategies in the Treatment of Young-Age Colon Cancer

Y. Nancy You, MD

Can We Apply Lessons Learned in the Rectal Cancer to Improve Surgical Outcomes in Colon Cancer

Brian K. Bednarski, MD

The Evolving Role of HIPEC in Gastric Cancer

Brian D. Badgwell, MD

Advances in the Systemic Therapy of Gastric Cancer

TBD

Panel Q & A**Case Presentations**

Moderator: Robert A. Wolff, MD

Panel: All Speakers

Monday, January 21, 2019

Session VIII	Cutaneous Oncology <i>Moderator:</i> Merrick I. Ross, MD
7:00-10:30am	Complete Dissection in Melanoma Patients with a Positive Sentinel Node: Is the Controversy Finally Resolved? Merrick I. Ross, MD Reconstruction After Resection of Cutaneous Malignancies of the Face and Scalp: Preserving Aesthetics Without Compromising Oncologic Outcomes David M. Adelman, MD Adjuvant and Neo-Adjuvant Therapy: Which Patients? What Therapy? Amaria Rodabe, MD Front-Line Therapy for Disseminated Melanoma: Current Standards and Future Directions Michael A. Davies, MD, PhD New Paradigm in the Treatment of Melanoma Brain Metastases: Are We Finally Making Progress? Michael A. Davies, MD, PhD Targeted and Immunotherapy for Advanced Non-Melanoma Skin Cancer Michael R. Migden, MD Panel Q & A Case Presentations <i>Moderator:</i> Merrick I. Ross, MD Panel: All Speakers; Robert H. Andtbacka, MD; Ana M. Ciurea, MD; Jeffrey E. Gershenwald, MD; Victor G. Prieto, MD, PhD Adjournment

**Presentations have been awarded ethics credit*

Copyright © 2019 The University of Texas MD Anderson Cancer Center. All rights reserved. No part of this work can be reproduced, distributed, or otherwise used without the express permission from The University of Texas MD Anderson Cancer Center.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping, and videotaping are prohibited.

PROGRAM INFORMATION

GOAL

The treatment of solid tumors continues to evolve and clinicians must stay abreast of the current information and recent therapeutic advances. Many tumor types require multidisciplinary treatment; many therapies previously studied only in advanced and metastatic settings are now applied in early curative stages as well. Healthcare professionals who care for cancer patients in different stages of disease need to understand the basis for these therapies. Additionally, HCPs must apply the preclinical and clinical data supporting the development and integration of these new therapies into their clinical practice.

This educational conference will interactively address current management controversies, updates, and novel therapies for multiple tumor types. It will bring together experts from multiple disciplines involved in the treatment of various solid tumors. The expected outcome is further integration of new cancer care developments into the clinical practice of surgeons, medical oncologists, radiation oncologists, and allied healthcare professionals who care for cancer patients.

EDUCATIONAL OBJECTIVES

After attending the conference, participants should be able to:

- Incorporate an appropriate sequence for surgical, radiation and chemotherapeutic intervention into treatment (*Knowledge, Competence, Performance*);
- Utilize different surgical, radiation, and systemic treatments including molecularly targeted therapies for these cancers at various stages of disease to improve patient outcomes (*Knowledge, Competence, Performance, Patient Outcomes*);
- Illustrate and implement the optimal treatment approach when given patient scenarios representing a range of stages, prognostic markers, and clinical presentations (*Knowledge, Competence, Performance, Patient Outcomes*);
- Interpret the clinical effectiveness of different treatment modalities based upon efficacy and toxicity parameters to ensure the most effective guidelines and outcome measurements (*Knowledge, Competence, Performance, Patient Outcomes*);
- Interpret and incorporate the novel therapies in the treatment of solid tumors including Breast Cancer, Lung Cancer, Head and Neck Cancers, Gastrointestinal Cancer, Genitourinary Cancer, and Melanoma (*Knowledge, Competence, Performance, Patient Outcomes*).

TARGET AUDIENCE

This program will be of interest to surgical oncologists, medical oncologists, radiation oncologists, diagnostic radiologists, pathologists, resident trainees, primary care physicians, advanced healthcare practitioners, physician assistants, nurses, fellows, and residents involved in oncologic care.

EDUCATIONAL METHODS

Lectures • Question and Answer Sessions • Case Studies • Meet-the-Professor Sessions • Audience Response System

EVALUATION

A course evaluation survey will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvements activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ACCREDITATION/CREDIT DESIGNATION

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 26.25 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ETHICS

The presentations marked with an asterisk (*) have been designated by The University of Texas MD Anderson Cancer Center for a total of 1.75 *AMA PRA Category Credits*[™] in medical ethics and/or professional responsibility.